WCA Recommendations for the Long-Term Treatment of Social Phobia
暂无分享,去创建一个
Dan J Stein | E. Hollander | D. Nutt | M. Pollack | J. Greist | S. Montgomery | R. Swinson | C. Allgulander | B. Bandelow | A. Okasha | M. Van Ameringen
[1] I. Holme,et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial , 2003, British Journal of Psychiatry.
[2] M. Liebowitz,et al. Results from a randomized, double-blind, multicenter trial of sertaline in the treatment of moderate-to-severe social phobia (social anxiety disorder) , 2002, European Neuropsychopharmacology.
[3] P. Doraiswamy,et al. Treatment of social anxiety disorder with citalopram , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[4] H. Wittchen,et al. Epidemiology, patterns of comorbidity, and associated disabilities of social phobia. , 2001, The Psychiatric clinics of North America.
[5] J. Davidson,et al. Impact of generalized social anxiety disorder in managed care. , 2001, The American journal of psychiatry.
[6] I. Holme,et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia , 2001, British Journal of Psychiatry.
[7] I. McKinnon,et al. Cigarette smoking and anxiety disorders. , 2001, JAMA.
[8] R. Bowen,et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. , 2001, The American journal of psychiatry.
[9] R. Bowen,et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. , 2000, Journal of clinical psychopharmacology.
[10] M. Stein,et al. Social phobia symptoms, subtypes, and severity: findings from a community survey. , 2000, Archives of general psychiatry.
[11] P. Farvolden,et al. Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI , 2000, Expert opinion on investigational drugs.
[12] S Kasper,et al. Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. , 2000, Journal of affective disorders.
[13] R. Kessler. The epidemiology, natural history, and pharmacoeconomics, of social anxiety and PTSD , 2000, European Neuropsychopharmacology.
[14] H. Wittchen,et al. Nicotine consumption in mental disorders: a clinical epidemiological perspective , 2000, European Neuropsychopharmacology.
[15] H. Westenberg. Neurobiology of anxiety disorders: Focus on neuroimaging , 2000, European Neuropsychopharmacology.
[16] D. Baldwin. Comprehensive treatment of social anxiety disorder , 2000, European Neuropsychopharmacology.
[17] D. Stein. Diagnostic dilemmas in social anxiety disorder and posttraumatic stress , 2000, European Neuropsychopharmacology.
[18] J. Davidson,et al. A placebo-controlled, double-blind study of pregabalin treatment of social phobia: Outcome and predictors of response , 2000, European Neuropsychopharmacology.
[19] D. Stein,et al. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta‐analysis of randomized controlled trials , 2000, International clinical psychopharmacology.
[20] P. Farvolden,et al. The neurobiology of social phobia: From pharmacotherapy to brain imaging , 2000, Current psychiatry reports.
[21] M. Antony,et al. Phobic Disorders and Panic in Adults: A Guide to Assessment and Treatment , 2000 .
[22] J. Rosenbaum,et al. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. , 2000, Journal of anxiety disorders.
[23] F. Schneier. Paroxetine in social phobia/social anxiety disorder , 2000 .
[24] D. Cicchetti,et al. Problems in developing an instrument for the rapid assessment of personality status , 2000, European Psychiatry.
[25] M. Ansseau,et al. [Guidelines for the treatment of anxiety disorders in adults]. , 2000, Revue medicale de Liege.
[26] Dan J Stein,et al. Functional brain imaging and pharmacotherapy in social phobia: Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram , 2000, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[27] J. Cottraux,et al. Cognitive Behavior Therapy versus Supportive Therapy in Social Phobia: A Randomized Controlled Trial , 2000, Psychotherapy and Psychosomatics.
[28] Dan J Stein,et al. Functional brain imaging and pharmacotherapy in trichotillomania Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram , 2000, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[29] T. T. Haug,et al. The treatment of social phobia in general practice. is exposure therapy feasible? , 2000, Family practice.
[30] M. Liebowitz,et al. Low dopamine D(2) receptor binding potential in social phobia. , 2000, The American journal of psychiatry.
[31] M. Stein,et al. Trends in the prevalence of social phobia in the United States: a synthetic cohort analysis of changes over four decades , 2000, European Psychiatry.
[32] A. Rossi,et al. The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. , 1999, The Journal of clinical psychiatry.
[33] M. Stein. Coming face-to-face with social phobia. , 1999, American family physician.
[34] Disability associated with social anxiety disorder , 1999, European Neuropsychopharmacology.
[35] R. Kessler,et al. Anxiety, mood, and substance abuse disorders: Patterns and correlates of comorbidity , 1999, European Neuropsychopharmacology.
[36] J. A. Boer,et al. Neurobiology of social anxiety disorder , 1999, European Neuropsychopharmacology.
[37] C. Allgulander,et al. Paroxetine in social anxiety disorder: a randomized placebo‐controlled study , 1999, Acta psychiatrica Scandinavica.
[38] R. Kumar,et al. Response to paroxetine is maintained during continued treatment in patients with social anxiety disorder , 1999, European Neuropsychopharmacology.
[39] M. Stein,et al. The history, epidemiology, and differential diagnosis of social anxiety disorder. , 1999, The Journal of clinical psychiatry.
[40] J. Davidson,et al. Treatment of social phobia with gabapentin: a placebo-controlled study. , 1999, Journal of clinical psychopharmacology.
[41] J. Ballenger. Clinical guidelines for establishing remission in patients with depression and anxiety. , 1999, The Journal of clinical psychiatry.
[42] R. Pioli,et al. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. , 1999, International clinical psychopharmacology.
[43] R. Kessler,et al. Lifetime co-morbidities between social phobia and mood disorders in the US National Comorbidity Survey , 1999, Psychological Medicine.
[44] J. Davidson,et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. , 1999, The American journal of psychiatry.
[45] R. Kessler,et al. Social fears and social phobia in a community sample of adolescents and young adults: prevalence, risk factors and co-morbidity , 1999, Psychological Medicine.
[46] J. Oakman,et al. Nefazodone in social phobia. , 1999, The Journal of clinical psychiatry.
[47] D. Klein,et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. , 1998, Archives of general psychiatry.
[48] J. Davidson,et al. Discontinuation of clonazepam in the treatment of social phobia. , 1998, Journal of clinical psychopharmacology.
[49] M. Stein,et al. Subtypes of social phobia and comorbidity with depression and other anxiety disorders. , 1998, Journal of affective disorders.
[50] J. Lépine,et al. Social phobia and alcoholism: a complex relationship. , 1998, Journal of affective disorders.
[51] M. Stein,et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. , 1998, JAMA.
[52] R. Kessler,et al. Social phobia subtypes in the National Comorbidity Survey. , 1998, The American journal of psychiatry.
[53] D. Stein,et al. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. , 1998, Journal of affective disorders.
[54] D. Klein,et al. Imipramine in the treatment of social phobia. , 1998, Journal of clinical psychopharmacology.
[55] M. Liebowitz,et al. Placebo-controlled trial of moclobemide in social phobia , 1998, British Journal of Psychiatry.
[56] H. Wittchen,et al. Prevalence of mental disorders and psychosocial impairments in adolescents and young adults , 1998, Psychological Medicine.
[57] Y. Lecrubier,et al. Comorbidities in social phobia , 1997, International clinical psychopharmacology.
[58] J. J. López-lbor,et al. Social phobia: a debilitating disease that needs treatment , 1997 .
[59] J. Davidson,et al. Moclobemide in social phobia: a controlled dose-response trial. , 1997, Journal of clinical psychopharmacology.
[60] H. Westenberg,et al. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. , 1997, The Journal of clinical psychiatry.
[61] L. H. Taylor,et al. Fluoxetine efficacy in social phobia. , 1997, The Journal of clinical psychiatry.
[62] E. Kleinknecht,et al. Cultural factors in social anxiety: a comparison of social phobia symptoms and Taijin kyofusho. , 1997, Journal of anxiety disorders.
[63] C M Miner,et al. The Brief Social Phobia Scale: a psychometric evaluation , 1997, Psychological Medicine.
[64] J. Davidson,et al. A 2‐Year Follow‐up of Social Phobia: Status After a Brief Medication Trial , 1996, The Journal of nervous and mental disease.
[65] M. Ameringen,et al. Paroxetine in social phobia. , 1996, The Journal of clinical psychiatry.
[66] H. Wittchen,et al. The impact of social phobia on quality of life , 1996, International clinical psychopharmacology.
[67] M. Stein,et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. , 1996, Journal of clinical psychopharmacology.
[68] M. Versiani,et al. The long-term treatment of social phobia with moclobemide , 1996, International clinical psychopharmacology.
[69] P. Bech,et al. Quality of life in anxiety and social phobia , 1996, International clinical psychopharmacology.
[70] M. Stein,et al. Panic disorder or social phobia: which is worse? , 1996, Behaviour research and therapy.
[71] R. Kessler,et al. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. , 1996, Archives of general psychiatry.
[72] M. Humble,et al. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase ‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study , 1995, Acta psychiatrica Scandinavica.
[73] K. Kobak,et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. , 1995, The American journal of psychiatry.
[74] R. Heimberg,et al. Dismantling cognitive-behavioral group therapy for social phobia. , 1995, Behaviour research and therapy.
[75] E. Leinonen,et al. Citalopram in the treatment of social phobia: a report of three cases. , 1994, Pharmacopsychiatry.
[76] H. Westenberg,et al. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine , 1994, Psychopharmacology.
[77] D. Beidel,et al. Social phobia: a comparison of behavior therapy and atenolol. , 1994, Journal of consulting and clinical psychology.
[78] M. Stein,et al. Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. , 1994, The American journal of psychiatry.
[79] J. Davidson,et al. Treatment of social phobia with clonazepam and placebo. , 1993, Journal of clinical psychopharmacology.
[80] E. Hollander,et al. Buspirone in social phobia. , 1993, Journal of clinical psychopharmacology.
[81] J. Rapoport,et al. Obsessive compulsive disorder in children and adolescents: issues in management. , 1993, The Journal of clinical psychiatry.
[82] T. Uhde,et al. Elective mutism as a variant of social phobia. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.
[83] M. Liebowitz,et al. Pharmacotherapy of Social Phobia , 1992, British Journal of Psychiatry.
[84] M. Weissman,et al. Social Phobia: Comorbidity and Morbidity in an Epidemiologic Sample , 1992 .
[85] J Gorman,et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. , 1992, Archives of general psychiatry.
[86] H. Westenberg,et al. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor , 1992, European Neuropsychopharmacology.
[87] M. Tancer,et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. , 1991, Archives of general psychiatry.
[88] K. Krishnan,et al. The Brief Social Phobia Scale. , 1991, The Journal of clinical psychiatry.
[89] G. Styan,et al. Relationship of social phobia with other psychiatric illness. , 1991, Journal of affective disorders.
[90] L. Kirmayer,et al. The Place of Culture in Psychiatric Nosology: Taijin Kyofusho and DSM-III-R , 1991, The Journal of nervous and mental disease.
[91] D. Regier,et al. Age at onset of selected mental disorders in five community populations. , 1990, Archives of general psychiatry.
[92] D. Munjack,et al. Clonazepam in the treatment of social phobia: a pilot study. , 1990, The Journal of clinical psychiatry.
[93] M. Stein,et al. Major depression in patients with social phobia. , 1990, The American journal of psychiatry.
[94] M. Liebowitz,et al. Tranylcypromine in social phobia. , 1988, Journal of clinical psychopharmacology.
[95] R. Noyes,et al. Anxiety symptoms distinguishing social phobia from panic and generalized anxiety disorders. , 1988, The Journal of nervous and mental disease.
[96] E. Hollander,et al. Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. , 1988, The Journal of clinical psychiatry.
[97] R. Mattick,et al. Treatment of severe social phobia: effects of guided exposure with and without cognitive restructuring. , 1988, Journal of consulting and clinical psychology.
[98] J. Gorman,et al. Phenelzine in social phobia. , 1986, Journal of clinical psychopharmacology.
[99] M. Gelder,et al. Exposure and anxiety management in the treatment of social phobia. , 1984, Journal of consulting and clinical psychology.
[100] M. Gelder,et al. Social Phobia: A Comparative Clinical Study , 1983, British Journal of Psychiatry.
[101] R. Harpin,et al. The Treatment of Social Phobia: Real‐life Rehearsal with Nonprofessional Therapists , 1981, The Journal of nervous and mental disease.
[102] C. Macfie. The year ... psychiatry. , 1980, The Medical journal of Australia.
[103] M. Liebowitz,et al. Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale. , 2002, Journal of anxiety disorders.
[104] R. Heimberg. Current status of psychotherapeutic interventions for social phobia. , 2001, The Journal of clinical psychiatry.
[105] D. Nutt,et al. Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. , 2001, The Journal of clinical psychiatry.
[106] J. Greist,et al. Social anxiety disorder: an unrecognized problem in primary care. , 2001, The Journal of clinical psychiatry.
[107] D. Stein,et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. , 2001, The Journal of clinical psychiatry.
[108] M. Antony,et al. Exposure-based strategies and social skills training. , 2000 .
[109] P. Ninan. Use of venlafaxine other psychiatric disorders , 2000, Depression and anxiety.
[110] J. Bobes,et al. Therapeutic advances: Paroxetine for the treatment of social anxiety disorder , 2000, Depression and anxiety.
[111] D. Klein,et al. Cognitive‐behavioral group therapy versus phenelzine in social phobia: Long term outcome , 1999, Depression and anxiety.
[112] D. Nutt,et al. Brain mechanisms of social anxiety disorder. , 1998, The Journal of clinical psychiatry.
[113] J. Biederman,et al. Attention-deficit/hyperactivity disorder: a life-span perspective. , 1998, The Journal of clinical psychiatry.
[114] M. Stein,et al. A direct-interview family study of generalized social phobia. , 1998, The American journal of psychiatry.
[115] C. Essau,et al. Häufigkeit und Komorbidität sozialer Ängste und sozialer Phobie bei Jugendlichen , 1998 .
[116] H. Westenberg,et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. , 1998, The Journal of clinical psychiatry.
[117] D. Pine,et al. Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. , 1997, Journal of child and adolescent psychopharmacology.
[118] The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. , 1997, European archives of psychiatry and clinical neuroscience.
[119] J. Angst,et al. Social phobia. , 1995, European archives of psychiatry and clinical neuroscience.
[120] R. Kessler,et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.
[121] E. Hollander,et al. Phenelzine and atenolol in social phobia. , 1990, Psychopharmacology bulletin.
[122] P. Clayton,et al. The comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. , 1990, The Journal of clinical psychiatry.
[123] J. Gorman,et al. Psychopharmacological treatment of social phobia. , 1985, Psychopharmacology bulletin.
[124] A. Mathews,et al. Brief standard self-rating for phobic patients. , 1979, Behaviour research and therapy.
[125] P. Shaw. The Treatment of Social Phobia , 1979 .